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Background: Many approaches exist to integrate protein-protein interaction data with other sources of information,
most notably with gene co-expression data, to obtain information on network dynamics. It is of interest to look at
groups of interacting gene products that form a protein complex. We were interested in applying new tools to the
characterization of pathogenesis and dynamic events of an Alzheimer’s-like neurodegenerative model, the AD11
mice, expressing an anti-NGF monoclonal antibody. The goal was to quantify the impact of neurodegeneration on
protein complexes, by measuring the correlation between gene expression data by different metrics.
Results: Data were extracted from the gene expression profile of AD11 brain, obtained by Agilent microarray, at 1,
3, 6, 15 months of age. For genes coding proteins in complexes, the correlation matrix of pairwise expression was
computed. The dynamics between correlation matrices at different time points was evaluated: paired T-test
between average correlation levels and a normalized Euclidean distance with z-score. We unveiled a differential
wiring of interactions in a set of complexes, whose network structure discriminates between transgenic and control
mice. Furthermore, we analyzed the dynamics of gene expression values, by looking at changes in gene-to-gene
correlation over time and identified those complexes that exhibit a different timedependent behaviour between
transgenic and controls. The most significant changes in correlation dynamics are concentrated in the early stage of
disease, with higher correlation in AD11 mice compared to controls. Many complexes go through dynamic changes
over time, showing the role of the dysfunctional immunoproteasome, as early neurodegenerative disease event.
Furthermore, this analysis shows key events in the neurodegeneration process of the AD11 model, by identifying
significant differences in co-expression values of other complexes, such as parvulin complex, with a role in protein
misfolding and proteostasis, and of complexes involved in transcriptional mechanisms.
Conclusions: We have proposed a novel approach to analyze the network structure of protein complexes, by two
different measures to evaluate the dynamics of gene-gene correlation matrices from gene expression profiles. The
methodology was able to investigate the re-organization of interactions within protein complexes in the AD11
model of neurodegeneration.
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The importance of understanding biological interaction
networks has stimulated the development of numerous
techniques, based on different physical principles, for
the generation of interaction data and the design of
analysis tools for such data. Usually cells networks are rep-
resented as graphs whose nodes correspond to molecules
(proteins, mRNAs, small molecules that are not encoded
by genes, and so on) and edges correspond to various types
of relationships among molecules (physical interactions,
enzymatic reactions, transcriptional activation, effects of
cell signaling components on downstream effectors). As a
consequence, many experimental methods have been de-
veloped with the aim to generate protein-protein inter-
action (PPI) networks.
PPI is one of the main organizational principles. PPI
networks are complex entities containing tens to thou-
sands of interactions which are rarely annotated with dy-
namic conditions (such as cellular environment) and
location information. Many approaches have been pro-
posed in the literature to obtain dynamic information
and integrate PPI data with other sources of information,
most notably with gene co-expression values [1-5].
Models of dynamic networks were also introduced in
the literature [6,7]. Usually cellular functions are not de-
termined by a single individual gene product: rather they
are determined by the interaction of gene products.
Thus, it is of interest to look at the behaviour of groups
of interacting gene products that form a protein com-
plex, either permanent or transient, or work as a bio-
logical process. Proteins complexes have been also
investigated from a dynamic perspective [8]. Interesting
studies on dynamics of complexes are presented in
[9-12].
Computational approaches to identify protein com-
plexes in a network are mainly based on extracting
highly interconnected, or dense, subnetworks in a PPI
network. Density can be considered in absolute terms,
i.e. the number of interactions among proteins in the
subnetwork, or can be the ratio of the number of inter-
actions within the complex to the number of interac-
tions with the rest of the network. The computational
approaches include MCL [13], CPM [14] and MCODE
[15]. Other approaches such as Align Nemo [16] identify
conserved complexes in two different species. From a
dynamic point of view, complexes can be stable or tran-
sient; an example of a stable complex is the proteasome,
while an example of transient complex is given by a kin-
ase interacting with its substrate. An interesting study
on dynamics of complexes is presented in [9] where it is
shown that proteins, that appear to be static in their cor-
responding gene expression levels during the cell-cycle
phases, are recruited by different complexes in different
phases. This was discovered by analyzing geneexpression data obtained by microarray experiments on
the same tissue, in different time points during the cellu-
lar cycle and relating these data with the PPI network
[10-12]. While the common interpretation of the dy-
namics of networks and of protein complexes is related
to changes over time, it is also of interest to apply the
same type of analysis to time series expression data col-
lected under different experimental conditions, for in-
stance healthy/unhealthy individuals, different tissues, or
different metabolic conditions.
The main focus of this paper is the analysis of the
interaction dynamics of protein complexes in neurode-
generative disease affected mice at different phases of
the pathology. We propose an approach to analyze the
dynamics of a complex investigating a set of gene ex-
pression microarray data [17,18], derived from mice ex-
pressing an anti-nerve growth factor (NGF) antibody,
called AD11 (see Methods) which develop a progressive
neurodegenerative pathology. The AD11 mouse repre-
sents a well characterized model of sporadic Alzheimer’s
disease [19,20]. The AD11 mice were analyzed at 1, 3, 6
and 15 months of age, versus the corresponding age-
matched control mice, with the goal of identifying the
early pre-symptomatic pathogenetic events and later
markers. The time point of 1 month corresponds to a
very early presymptomatic phase of the progressive neu-
rodegeneration. We identified those functional com-
plexes (contained in the analyzed network) that exhibit a
different behaviour of constituent proteins, in control
and AD11 mice at different stages of the disease. We in-
vestigated the difference in the correlation between gene
pairs in the known complexes between AD11 and con-
trol during the different stages of the disease. Correl-
ation of gene pairs is measured by the value of Pearson
Coefficient producing, for each complex, a matrix of
gene co-expression values. The workflow of our analysis
is outlined in Figure 1. Our approach adopts two differ-
ent measures to compare the two correlation matrices
associated to gene pairs within a complex of AD11 and
control: a) one is the difference in the average correl-
ation of the matrices; b) the other is the distance be-
tween the two matrices. We compared every protein
complex in transgenic and control mice in each time
point using the above measures. Data analysis reveals a
set of complexes whose dynamics likely discriminate be-
tween diseased and control mice. Furthermore, we ana-
lyzed the dynamics of gene expression values in AD11
looking at the changes in gene-to-gene correlation over
time and identified those complexes that exhibit a differ-
ent time-dependent behaviour between transgenic and
control mice. Concerning the timing of variations along
lifespan, the most significant changes in average correl-
ation are concentrated in the early stage of the disease,
with a higher correlation in AD11 mice compared to
Figure 1 Workflow of analysis. The analyzed dataset includes 16,515 mRNA probes and 30 experiments (15 experiments for controls and 15
experiments for AD11) for each of the four time points (1, 3, 6, 15 months of age), corresponding to the progressive neurodegeneration. From
these data, we computed the whole gene-gene correlation matrix and extracted the sub-matrices corresponding to the selected protein
complexes, as described in CORUM database (see Methods). Control and AD11 matrices are compared using the chosen metrics.
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plexes are involved in the neurodegeneration and go
through dynamic changes over time in AD11 mice.
Results
Comparative analysis of gene co-expression values in
complexes of AD11 and control over time
We report on the correlation strength of the expression
values of genes whose encoded products form protein
complexes, and discuss if a different marking is present
in such strength between the AD11 transgenic mice and
the controls.
We used two different measures to determine the
changes of co-expression values:
a) the difference of the average co-expression level be-
tween AD11 and control matrices;
b) the distance between the co-expression matrices of
AD11 and control.
The measures (detailed in Methods) differ in one import-
ant aspect: while in a) the sign of co-expression values is
taken into consideration in the computation of the average,
in b) the difference of corresponding elements in the two
matrices is taken in absolute value and therefore only its
magnitude is taken into account. Therefore the two mea-
sures reveal different aspects of the behaviour of the co-
expression values.Difference of average co-expression levels in complexes
For a given complex of size n we computed the co-
expression values of the n(n− 1)/2 pairs of genes encoding
the proteins forming the complex using the Pearson correl-
ation coefficient of the gene expression profiles. Such values
are arranged in an upper triangular matrix A with n rows
and n columns, where element Aij corresponds to the cor-
relation between the expression values of genes i and j. This
computation was repeated for each of the four time points
(months 1, 3, 6, 15), resulting in four matrices denoted by
A1, A3, A6, and A15 for AD11 data and by B1, B3, B6, and
B15 for the control data. Then, for each of the obtained
matrices, the average value was computed over all its en-
tries. At any time point t, the difference between the aver-
ages of AD11 and control matrices At and Bt gives an
indication of the correlation change within a complex. To
evaluate the significance of the change, we applied the t-
student statistical test with a threshold p = 0.05 (see
Methods). This test generated a binary quadruplet (t1, t3, t6,
t15) of +1, 0, −1 numbers, where +1 indicates a significant
positive variation AD11 vs. control, −1 a significant negative
variation, and 0 no significant modification. The quadruplet
associated with a given protein complex enables to immedi-
ately visualize at which stage of the disease, if any, a signifi-
cant difference in the gene-gene correlation of AD11 vs.
controls occurs.
Table 1 reports the binary quadruplets associated to
complexes of size greater than 3 that are different from
Table 1 Variation in average correlation levels between AD11 and controls
Quadruplets: AD11 vs. Control
COMPLEX Size t1 t3 t6 t15
Parvulin-associated-pre-rRNP-complex 40 1 0 0 −1
20S-proteasome 14 1 0 0 0
immunoproteasome 14 1 0 0 0
B-Ksr1-MEK-MAPK-14-3-3-complex 8 0 0 −1 0
Gata1-Fog1-MeCP1-complex 8 0 1 0 0
Drosha-complex 7 1 0 0 0
BLOC-1-biogenesis-of-lysosome-related-organelles 6 0 0 −1 0
Metallothionein-3-complex 6 0 0 0 −1
Brd4-Rfc-complex 5 1 0 0 0
MCM-complex 5 1 −1 0 0
Agap11-AP3-complex 4 1 0 0 0
Kif3-cadherin-catenin-complex 4 1 0 0 0
Sarcoglycan-sarcospan-syntrophin-dystrobrevin 4 0 0 1 0
Wave-2-complex-Rac-activated 4 −1 0 0 0
The binary quadruplet (column 3) represents the significance of the difference in average correlation (obtained from gene expression profiles) between AD11
(disease affected) and control data in a complex at the 4 different time points (1,3,6,15 months of age). Size is the number of genes in the complex. Only
complexes with size > 3 and with quadruplet different from (0 0 0 0) are reported. The complexes are listed according to their size. Significant values (+1/-1) are
highlighted in bold.
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fected at month 1, i.e. at the very early stages of the dis-
ease. Precisely, 9 out the 14 complexes listed in the table
have a non-zero value as the first element of the quadru-
plet, with 8 out of 9 values equal to +1, while from
3 months onward only few cases are significant and
most of them are equal to -1. This can be interpreted as
a general stronger internal correlation in the very early
stage of disease in AD11 vs. control mice, while the op-
posite occurs later in life. This also suggests that most of
the crucial events triggering the disease in this model
occur very early in life. The majority of analyzed com-
plexes (27 out of 39 with size >3) have difference in
average co-expression very close to 0 and are associated
with (0, 0, 0, 0) quadruplets (Table 1). They are not re-
ported in the table and will be analyzed from a different
perspective in the next subsection.Distance of co-expression matrices of AD11 and control
complexes
To further justify the second type of analysis we ob-
served that the behaviour of the complex might not be
the same in AD11 and control, even without significant
variation of the average co-expression, for example if the
standard deviation of co-expression values within such
complexes is too high for a significant t-test. Thus we in-
vestigated all complexes to check whether we can iden-
tify new complexes not revealed by the previous
measure. To that end, as mentioned, we used a differentmeasure of similarity of co-expression values, based on
the difference of co-expression levels of corresponding
pairs of genes in AD11 and controls. In this way we can
reveal both positive and negative changes due to single
components of the two correlation matrices even if the
average of the two matrices is similar.
Given two co-expression matrices, we defined their
distance d as the square root of the normalized sum of
the squared differences over the elements of the matri-
ces (more details in Methods). For each protein com-
plex, such distance is calculated for the four time points,
generating a vector representation composed of four







t is the distance between the
two matrices at time t. To evaluate the statistical signifi-
cance of the distance values, we computed the z-score of
these values by comparing them to control values ob-
tained for random complexes, as explained in Methods
section. Table 2 reports the results of this computation
applied to AD11 and control data at the four time
points. The quadruplets of distance values revealed that
for some complexes such values are not uniform; rather,
there are peaks indicating a more pronounced variation
at some specific time points. Consistently with the re-
sults presented in the previous section, we noted that
the most significant values of the distance (z-score > 1.9)
occur at 1 month of age. Indeed, this is confirmed by
the average distance dAD11−Controlt over all complexes (in-
cluding those not reported in the table) which is higher
Table 2 Distances between correlation matrices of AD11 and controls
Distance: AD11-Control
COMPLEX Size d1 d3 d6 d15
immunoproteasome 14 0.26 0.14 0.2 0.16
(2.22) (−2.45) (−0.22) (0.19)
Mediator-complex 7 0.29 0.2 0.16 0.11
(2.10) (0.09) (−1.00) (1.17)
Wave-2-complex-Rac-activated 4 0.33 0.07 0.33 0.36
(1.98) (−1.85) (1.97) (3.39)
p97-Ufd1-Npl4-IP3-receptor-complex 4 0.34 0.21 0.16 0.20
(2.14) (0.31) (−0.56) (0.86)
Tis7-Sin3-Hdac1-Ncor1-Sap30-complex 4 0.34 0.2 0.12 0.03
(2.14) (0.16) (−1.16) (−1.81)
Axin-Dvl-Gsk-Frat1-complex 4 0.28 0.33 0.13 0.1
(1.20) (2.17) (−1.01) (−0.7)
PYR-complex 10 0.19 0.16 0.17 0.27
(−0.67) (−1.22) (−0.98) (3.20)
PU,1-associated-protein-complex 4 0.21 0.21 0.21 0.3
0.11) (0.31) (0.18) (2.44)
TFIID-complex 7 0.25 0.15 0.17 0.2
(1.09) (−1.16) (−0.76) (2.15)
ORC-complex-origin-recognition-complex 4 0.21 0.18 0.27 0.27
(0.11) (−0.14) (1.07) (1.97)
The distances of AD11 and control matrices at the 4 different time points (1,3,6,15 months of age) are reported in columns (d1, d3, d6, d15) respectively. The
z-score of each value is reported in parentheses below the value itself. Size is the number of genes in the complex. Only complexes with size > 3 and with at least
a z-score value above 1.9 are reported. Negative z-scores indicate a distance AD11 vs. control matrices smaller than the random expectation. Significant z-scores
are highlighted in bold.
Arisi et al. BMC Neuroscience  (2015) 16:28 Page 5 of 15at 1 month than at 15 months of age (0.2 and 0.14, re-
spectively). The first 5 complexes listed in Table 2 dif-
fer between AD11 and control at 1 month of age,
specifically: immunoproteasome, Mediator complex,
Wave-2-complex-Rac-activated, p97-Ufd1-Npl4-IP3-
receptor-complex,Tis7-Sin3-Hdac1- Ncor1-Sap30-
complex while for Axin-Dvl-Gsk-Frat1-complex an
high value of the z-score is present at 3 months of age.
The complex Wave-2-complex-Rac-activated is the
only one in Table 2 with three high z-score values (at
month 1, 3 and 15). Furthermore, along with the
immunoproteasome complex, Wave-2-complex-Rac-
activated was also highlighted in the previous analysis
(Table 1). From the results in Table 1 and Table 2, the
presymptomatic phase of the disease (1 month) is
where the majority of significant changes occur.
Discussion
We have investigated, by a correlation analysis, the
gene expression data, corresponding to protein com-
plexes, in samples of transgenic mice expressing an
anti-NGF antibody and developing a progressive
form of neurodegeneration (called AD11), comparedto age-matched controls. This led to the identifica-
tion of complexes showing a relevant difference in
co-expression values mostly at 1 month. Some of
these complexes will be presented below and the
possible functional significance in the neurodegener-
ation will be discerned.
Parvulin-associated pre-rRNP complex
This complex was isolated by immunoprecipitating par-
vulin from mouse and human cells. The complex is
formed by preribosomal RNAs, at least 26 ribosomal
proteins and 26 factors involved in rRNA processing and
assembly at an early stage of ribosome biogenesis [21].
Those are likely to be involved in ribosome assembly
and nucleolar assembly. Human parvulin (hParvulin;-
Par14/EPVH) [22] belongs to the third family of
peptidylprolylcis-trans isomerases that exhibits an en-
zymatic activity of interconverting the cis-trans con-
formation of the prolyl peptide bond, and shows
sequence similarity to the regulator enzyme for cell cycle
transitions, human Pin1. Pin1 is involved in the patho-
genesis of certain cancers and protein folding patholo-
gies, in particular aberrant Amyloid processing and Tau
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disease [23-26]. Even though the structure of the com-
plex is significantly different for AD11 and control mice
both at 1 month and at 15 months of age, we will focus
on the early stage because of our interest in the pre-
symptomatic phase of the disease. Figure 2 shows the
whole correlation matrices for the complex at 1 month
of age, but also the difference matrix, where the Ddx5
row and column appear as the most anti-correlated
within the matrix. Ddx5 (better known as P68) is aFigure 2 Correlation in Parvulin complex at 1 month of age. Whole correla
control mice (top and center), and the difference matrix (bottom) at 1 mon
go from −1.0 (red) to +1.0 (green). The correlation structure is globally very
the Ddx5 gene row and column that show a strong anti-correlation in AD1
shown on the bottom right, as obtained from the StringDB online tool. Thmember of DEAD box helicases family and a cofactor
to a number of proteins involved in brain development
and cell proliferation. Ddx5, and its closely associated long
non-coding RNA steroid receptor RNA activator (SRA),
act in different complexes and signaling systems, including
Estrogen Receptor and Notch [27]. Estrogen Receptors,
expressed both in neurons and glia, coupled to Ddx5 that
shows an age- and sex dependent expression level, are
crucial for nervous system development [28]. Ddx5 has
also been proved to have a key role in development fortion matrices of Parvulin-associated pre-rRNP complex in AD11 and
th of age. The gene symbols are along the matrix. Correlation values
different, in particular the red arrows in the difference matrix highlight
1 compared to control. The protein complex interaction network is
e Ddx5 protein appears as very poorly connected to the network.
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of Ddx5 in cell proliferation and cancer and the role of
NF-κB as one of the identified Ddx5 interactors have been
proved [30]. In Figure 2 the network structure is shown,
as generated by the StringDB online tool: the Ddx5 pro-
tein appears as one of the least connected, suggesting this
is a critical node of the complex. In our study, the heavy
anti-correlation of Ddx5 towards the other complex mem-
bers, may suggest that at 1 month the complex negatively
regulates the active participation of the gene in this spe-
cific complex, but not in others, as suggested by the roles
in several other cellular functions. Later in life, after
3 months of age in the AD11 model, Ddx5 is recruited
again at the same level as control. It has been reported
that Ddx5 regulates the splicing of tau gene [31], a protein
critical for cytoskeleton maintenance and axonal transport
and a key player in AD: this suggests that the early anom-
aly in the Parvulin complex, may trigger the tauopathy ob-
served that appears in the AD11 model from 2–4 months
onwards [18,19].20S Proteasome complex
20S proteasome is a stable complex for which the crystal
structure is available in the protein data bank (PDB).
Overall data indicate a decline in the Proteasome complex
correlation, which is likely to correspond to a decline in
the molecular efficiency. Proteasome dysfunction and in-
sufficient removal of misfolded proteins are crucial actors
in neurodegenerative pathologies [32-34].
One of the classical hypothesis to explain the patho-
genesis of sporadic forms of AD, is a defective clearance
of tau and Aβ protein aggregates. The degradation of Aβ
depends on a number of different proteases, some of
them only active in specific cellular compartments, with
the proteasome active in the cytosol [35]. The alteration
of this delicate equilibrium may favour intra and extra-
cellular Aβ accumulation. Conversely, the Aβ40 and
Aβ42 fragments, both in oligomeric and fibrillary forms,
were shown to negatively interfere with proteasome
complex function in vitro, by an inhibition of the enzym-
atic activity. This suggests a negative feedback further
impairing proteasome function [36]. Similarly to Aβ, the
abnormal aggregation of misfolded tau protein leads to a
neurofibrillary pathology, generating insoluble aggregates
common to several neurodegenerative forms, such as
AD and other tauopathies. Many experimental findings,
though not all of them, show an impaired core-
proteasome activity in AD samples [37], suggesting an
impairment of the proteasome with ageing followed by
an incomplete clearance of tau protein, which is nor-
mally soluble and degraded by the proteasome. We can
hypothesize that, in AD11 model, a dysfunctional prote-
asome in the pre-symptomatic phase (1 month of age),should favour an early but progressive accumulation of
tau aggregates [38].
Immunoproteasome complex
The immunoproteasome complex is similar to the 20S
proteasome, except for the catalytic β subunits Psmb5,
Psmb6, Psmb7 that are replaced by Psmb8, Psmb9,
Psmb10. Its role is connected to cleaving peptides that
will be associated by MHC class I molecules [39], to
gamma-interferon induced response [40], but also to
protect from oxidative stress, as shown in Psmb10 and
Psmb8 (−/−) KO mice [41]. The immunoproteasome
complex has been shown to exhibit much reduced sta-
bility relative to standard proteasomes, coherently with
the capacity of the immune system to efficiently respond
to antigens. Moreover, a decreased stability is a mechan-
ism for a rapid but flexible reaction [42]. The immuno-
proteasome shows different dynamics along lifespan,
compared to 20S-Proteasome complex, since the qua-
druplets in Table 1 are (1,0,0,0) for both, but in Table 2
the 20S-Proteasome complex is absent, highlighting a
significantly different network dynamics of these two
complexes. At 1 month, the AD11 mouse shows a high
correlation between complex members, except for
Psma7 gene, which is clearly anti-correlated, thus in
some way dissociated from the immunoproteasome net-
work, according to our interpretation of the correlation
as measure of protein-protein association. In control
mice, a similar anti-correlation occurs with Psmb10
gene, in the context of a general lower correlation be-
tween nodes. The general differential correlation be-
tween AD11 and control at 1 month disappears at
3 months of age, when both mice show a similar correl-
ation pattern (Figure 3), as if in AD11 the immunopro-
teasome system takes much longer to reach the
physiological state. The difference at 1 month is mainly
attributable to: Psma7 anti-correlated to all the other
genes in AD11 immunoproteasome complex, Psmb10
anti-correlated mostly to α subunits of complex, and to
a lesser extent Psmb9. Psma7 is negatively correlated
with interferon based response to viral antigens [43], fur-
thermore Psma7 depletion inhibits cancer growth, being
heavily involved in cell cycle and transcription control
[44]. The differential behaviour of Psma7 and Psmb10 in
our data suggests a dysfunctional immunoproteasome,
where a highly correlated Psmab10 in AD11 mice, may
have been the consequence of an anomalous immune re-
sponse or an inflammatory response, able to directly
regulate immunoproteasome specific subunits, including
Psmb10 [45].
Overall, literature reports that proteasome system is
affected in neurodegeneration. Whether the proteasome
system, including immunoprotesome, is impaired or
over-activated, remains a controversial question, both in
Figure 3 Correlation in immunoproteasome complex. Triangular correlation matrices of immunoproteasome complex in AD11 and control mice
at l, 3, 6, and 15 months of age. The gene symbols are along the matrix. Correlation values go from −1.0 (red) to +1.0 (green). The blue arrows
indicate that changes in the correlation network are statistically significant only at l month, both from metrics in Table 1 and Table 2. At l month
of age, the genes within the complex in AD11 mice are heavily correlated, with the notable exception of Psma7 gene, while in control mice the
average correlation is smaller and the only clearly anti-correlated gene is Psmb10. These two genes are highlighted in red.
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seem more in favour of an abnormal activation of immu-
noproteasome and a decreased activity of proteasome
and ubiquitin systems, as shown in human AD and
animal models [37,46,47].
Some authors suggest an apparent global down-
regulation of the proteasome and immunoproteasome
systems [47]. Other findings show a higher activation of
immunoproteasome in brain of AD patients compared
to the brain of non-demented elderly, being its expres-
sion in young brain negligible or absent. Furthermore,
AD affected regions show a partial decrease in prote-
asome trypsin-like activity [37].
This is in agreement with the well known involvement
and activation of inflammatory and immune system in
human neurodegenerative diseases: a classical example is
the activation of astrocytes around Aβ plaques. The dif-
ferent reports may be originated by biological variability
and different experimental protocols to assess the prote-
asome activity, unable to discriminate between the pro-
teasome core units and the immunoproteasome [37].
Mediator complex
The mediator complex plays a crucial role in transcrip-
tional mechanisms, acting as a bridge between a largeset of transcription factors and RNA Pol II, thus modu-
lating Polymerase activity. This role seems to be medi-
ated by structural modification of the complex [48]. The
mediator complex proteins are involved in a large variety
of cellular processes such as transcription initiation and
elongation, the formation of loops that establish connec-
tions between enhancer sequences and promoters, mod-
eling the chromatin structure by mediating its epigenetic
modifications [49]. Moreover the role of the complex as
a whole has been demonstrated in a variety of syn-
dromes, including malignancies and cardiovascular path-
ologies [50]. This complex has been shown to regulate
also neuronal system development, through the tran-
scriptional modulation of specific genes such as Sox9
[51]. The correlation pattern between AD11 and control
mice is essentially similar from 3 months onward, but at
1 month of age Med6 and Thrap3 are anti-correlated in
AD11 (Figure 4). This anti-correlation may correspond
either to an incomplete complex or to a negative modu-
lation of transcription. Thrap3 closely interacts (as
proved by co-immunoprecipitation) with Clock (circa-
dian locomotor output cycles kaput) and Arntl (also
known as Bmal1 (aryl hydrocarbon receptor nuclear
translocator-like), two genes that form an heterodimer
and are key players in the circadian cycle [52] and a
Figure 4 Correlation in Mediator complex. Triangular correlation matrices of mouse Mediator complex (according to CORUM database) in AD11
and control mice at 1, 3, 6, and 15 months of age. The gene symbols are along the matrix. Correlation values go from −1.0 (red) to +1.0 (green).
The blue arrows indicate that changes in the correlation network are statistically significant only at 1 month in Table 2. At 3, 6, 15 months of age
the correlation matrices are similar, but at 1 month Med6 and Thrap3 (also known as Trap150) are heavily anti-correlated only in AD11 mice.
These two genes are highlighted in red.
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onal survival. This underlines the connection between
an altered circadian clock and brain ageing [53]. The
Med6 subunit is a key component of the head module of
Mediator complex [54]. When immunoprecipitated,
Med6 seems to mediate the transcriptional modulation
through different mechanisms compared to other com-
plex subunits, such as Cdk8; in particular it seems to act
indirectly on Polimerase II, without exerting a phosphor-
ylation action [55]. In our data, the anti-correlation of
Med6 and Thrap3 in relation to the other subunits may
indicate an aberrant general transcriptional control and
chromatin maintenance at an early time point of the
neurodegenerative process.
Drosha complex
The Drosha complex is essential for microRNA maturation,
a well known subclass of small non-coding RNAs. Along
with DBCR8, an RNA-binding protein, it forms the com-
plex known as Microprocessor which processes long pri-
mary microRNAs. Drosha functions as the catalytic
subunit, while DGCR8 recognizes the RNA substrate. Links
between microRNA and neurodegenerative diseases have
been well established. The microRNA expression profiles
are significantly affected in neurodegeneration, both in thebrain of human AD [56] and animal models [57,58] and in
peripheral blood, where they are potential disease bio-
markers [59,60]. This alterations are not simply down-
stream disease biomarkers of the pathological state, but the
signature of an active role played by microRNAs in the
neurodegenerative process, for example interfering with the
tau network and amyloid networks in AD [61,62]. In par-
ticular, the role of Drosha and Dicer complexes in neurode-
generation has been shown in Huntington’s disease models
[63] and Dicer Knock-out models, where Dicer ablation
leads to a neurodegenerative phenotype [64]. Therefore, the
identification of alterations in the Drosha complex struc-
ture, not only underlies a general regulation of gene expres-
sion mediated by microRNAs, but appears also critical for
the neurodegenerative cascade.
Metallothionein-3-complex
Metallothionein-3 is a component of a multiprotein
complex which very early on was associated with neuro-
logical disorders in humans [65]. Numerous successive
experiments confirmed this association by showing that
MT-3 is decreased considerably (by 30%) in brains of pa-
tients with AD [66]. Furthermore ZnMT-3, being able to
bind bivalent ions, is neuroprotective against Aβ40 and
Aβ42 fragments associated to Cu2+ in vitro and in vivo
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for this complex indicates a significant difference be-
tween AD11 and control samples at 15 months of age,
and this disfunction in the overt phase of the disease is
very similar to what is observed in human AD.
MCM complex
Minichromosome maintenance (MCM) is a component
of the pre-replication complex (pre-RC) and may be in-
volved in the formation of replication forks and in the
recruitment of other DNA replication related proteins
[69]. MCM proteins are necessary for DNA replication
initiation and progression in the cell cycle [69,70]. Mem-
bers of the MCM family were found to be phosphory-
lated and associated to neurofibrillary tangles and
amyloid plaques in AD neurons [70]. It was also experi-
mentally determined that the interaction of MCM pro-
teins with protein FE65 may contribute to the neuronal
cell cycle re-entry observed in Alzheimer’s disease (AD)
brains [71]. The fact that in our study MCM complex
shows a significant variation in AD11 mice from 1 to
3 months and not afterwards, suggests an early interfer-
ence with ordinary neuronal cell cycle, which could lead
to apoptosis or anomalous proliferation [72].
Wave-2-complex-Rac-activated
Wave-2 is a member of WASP/WAVE family of the
actin cytoskeletal regulatory proteins. Our results indi-
cate a strong change in co-expression values between
AD11 and controls using both measures of distance
(Table 1 and Table 2). This, in accordance with recent
findings reported in the literature, links this protein
complex to neurodegenerative pathology: WAVE accu-
mulation was associated to neurofibrillary tangles and
Aβ both in the 3xTg-AD animal model and AD human
samples [73]. For instance, one component of Wave
complex, the protein Nckap1, was found to be markedly
reduced in AD-affected human brains [74].
Conclusions
This work was aimed at analyzing the internal correla-
tions of genes corresponding to protein complexes in
the brain of a transgenic model of neurodegeneration,
the anti-NGF AD11 mouse. More precisely, we tried to
quantify how much the neurodegenerative process af-
fects the protein complexes, by measuring the correl-
ation between gene expression profiles. In our approach,
Pearson correlation between gene expression data corre-
sponding to proteins belonging to a certain protein com-
plex is taken as a mediated measure of their physical
association, within the experimental conditions. Previous
works [6,75-77] have investigated the relationship of
protein interactions and gene expression for many of the
known protein complexes. These studies have shownsignificant co-expression, both in terms of similarities of
mRNA levels and expression profiles, between the sub-
units of protein complexes. Building on previous analysis
of gene correlation within complexes, we have developed
an analysis methodology with the aim of exploiting the
behaviour of these correlations in time, i.e., their dynam-
ics in disease vs. control mice. The proposed method is
innovative as it considers two different techniques, and
their proper statistical testing, to analyze the dynamics
expressed by the change of matrices over time. We
coupled a more standard evaluation of average correl-
ation to a different metric, in order to detect different
dynamical features. This second approach unveiled a
hidden dynamics that could not be described by an
evaluation of the average connections. Indeed only two
complexes appear significant with both approaches
(Table 1 and Table 2): the immunoproteasome and the
Wave-2-complex-Rac-activated. This suggests that, even
if often the average correlation does not change signifi-
cantly across lifespan, the internal structure undergoes a
rewiring of interactions. Concerning the timing of varia-
tions along the mouse lifespan, significant changes in
average correlation are concentrated at 1 month of age,
with a higher correlation in AD11 mice compared to
controls. Later in life significant changes occur without a
precise timing and are mostly negative, that is in the dir-
ection of a smaller average correlation in AD11 mice. A
higher correlation at 1 month of age, the first analyzed
time point, may suggest that at this early stage the brain
complexes show a more rigid structure in the AD11
model compared to control, while at later stages there
may be more flexibility, with an opposite behaviour and
thus a less correlated network in the AD11 model
(Table 1). According to the second used metric, the dis-
tance between correlation matrices, statistically significant
variations occur both at 1 month and at 15 months of age,
that is before the onset and at the end of the disease pro-
gression (Table 2). The two different metrics essentially
target unrelated features of the complexes, as proved by
the fact that many complexes unaffected according to the
first metric (not included in Table 1), are significant in the
second approach (Table 2). The first metric is a measure
of a general strength of the interactions by the average
correlation level, while the second metric is a measure of
the re-organization rate within the complex: stronger in-
teractions are likely to be associated to less flexible net-
works and vice versa.
Looking into the detailed structure of the correlation
matrix at 1 month of age, we found notable cases of sin-
gle genes affected within the complexes (Figures 2, 3,
and 4), being heavily anti-correlated to most of the other
complex members. This is a further level of analysis that
targets the connections of single players in the complex:
a single node may trigger the full functionality, or a
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nected or un-connected to the network. This is particu-
larly interesting in the case of the immunoproteasome
complex, where it is clear that a compact complex, with
a correlated general structure in AD11 mice at 1 month
of age, is coupled with a strongly anti-correlated Psma7
subunit, while in control mice the un-connected subunit
is a different one, Psmb10. The recruitment (transition
from uncorrelated to correlated) of different complex
subunits at different timing is certainly deeply affecting
the biological function. In this respect, we suggest an in-
dependent validation of this prediction by targeting
protein-protein interactions by monoclonal antibodies,
able to disrupt specific nodes or edges inside an inter-
action network.
We previously characterized transcriptomics profiles
in the AD11 model [18] and showed that the absolute
peak of differential expression vs. control mice is at
3 months of age in cortex. Interestingly, a significant dif-
ferential gene expression was identified in the AD11
hippocampus at 1 month of age, mainly related to an al-
teration in the expression of the inflammation/immune
system genes. In the present study the significant
changes take place mostly at 1 month and only partially
at 15 months. The difference between the present study
and our previous one [18] may derive from different
mechanisms underlying two distinct phenomena: on the
one hand, up- or down-regulation of single genes and,
on the other hand, the correlation patterns of function-
ally related genes that we have associated to protein-
protein interactions within complexes. In this study the
link of immune system with the neurodegenerative
process was confirmed, meanwhile the unexpected
role of Parvulin, Mediator and Drosha complexes,
highlighted an early involvement and dysregulation of
gene expression in neurodegeneration processes, at the
transcriptional (Mediator), post transcriptional (Drosha)
and translational (Parvulin) levels. Moreover, the identi-
fication of proteasome and immunoproteasome com-
plexes highlights the early alteration of protein
homeostasis, potentially a prerequisite of misfolding, in
the early neurodegeneration process. Since the AD11
mouse at 1 month of age is pre-symptomatic, because
there is no apparent neurodegenerative and/or behav-
ioural altered phenotype, this finding is even more sig-
nificant. A dysfunction in the interaction structure of
key critical protein complexes parallels a gene expression
alteration.
We plan to validate our results by the use of a prote-
omic methodology, thus a global approach such as mass
spectrometry or protein arrays, coupled to the isolation
of single complexes, since this is now feasible by recent
techniques [78]. A proteomic approach will allow, for
example, to assess if the correlation/uncorrelation statusof specific proteins is associated to a stable/transient
membership to corresponding complexes, and to find a
relation between genomic and proteomic profiles.
We conclude that this novel approach is able to unveil
an internal rewiring of interactions within protein com-
plexes, even when there is no apparent change in the
average correlation level. The neurodegenerative process
in the AD11 mouse model is affecting not only the glo-
bal gene expression profile along lifespan, but also the
efficiency of key molecular machinery, by modulating
the interaction network within crucial protein com-
plexes. These might be key events in the pathogenesis
and development of AD.
Methods
Our analysis integrated gene expression data with PPI
data. Time series gene expression data correspond to
two different classes: AD11 and control mice. PPI data
were derived from public datasets. In the following we
provide details.
Microarray dataset
AD11 transgenic mice [19,20] express a recombinant
version of the monoclonal antibody mAb αD11 that spe-
cifically recognizes and neutralizes NGF [79,80]. AD11
anti-NFG mice were produced by crossing mice that ex-
press the heavy chain of the transgenic antibody (VH
mice) with mice that express the light chain of the anti-
body (VK mice). As in previous studies [18], VH mice
were used as transgenic control mice that are consist-
ently negative with respect to all the classical neurode-
generation markers (molecular, cellular and behavioural).
The brain tissue from a total of 60 female AD11 mice
and 60 female VH control mice was used for this study,
divided into 15 AD11 and 15 controls for each of the
four time points (1, 3, 6, 15 months of age).
The microarray data for the transgenic mouse were
provided by the European Brain Research Institute
(EBRI, Roma, Italy). The gene expression dataset was ob-
tained by Agilent two-color microarray platform (44 K
and 4x44K mouse whole genome chips, grid ID 012694
and 014868). The whole dataset is publicly available
from the Gene Expression Omnibus database.
The dataset includes 16,515 mRNA probes and 30 ex-
periments for each time point (15 experiments for con-
trols and 15 experiments for AD11), for a total of 120
experiments. The output gene profiles for the entire gen-
ome is thus represented by 8 matrices with 15 columns
and 16,515 rows, each row representing one mRNA ex-
pression profile. Filtering was applied to the microarray
data (Figure 1). Since different probes may match the
same gene, we selected only the probes that allow the
best discrimination between control and AD11 classes.
To do that, we used the ANOVA (Analysis of Variance)
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sponse variable (continuous random variable) measured
under conditions defined by discrete factors. After this ini-
tial filtering, we also removed the probes corresponding to
genes not present in the protein complexes considered in
this analysis, as described in CORUM database (see below).
The final dataset contains 559 mRNA probes.
Protein complexes
Protein complexes annotation was extracted from the
Comprehensive Resource of Mammalian protein com-
plexes database (CORUM) [81]. This database provides a
resource of manually annotated protein complexes from
mammalian organisms. Annotation includes protein com-
plex function, localization, subunit composition, literature
references and more. All information included in CORUM
was obtained from individual experiments published in sci-
entific articles (unreliable data from high-throughput exper-
iments are excluded). Of the CORUM dataset we
considered the subset of protein complexes for which the
gene expression data were available in our dataset. Further-
more, after this filtering that reduced the size of a number
of complexes we selected the complexes with size greater
than or equal to 3, resulting in a final set of 81 complexes
of size ranging from 3 to 40.
Constructing the gene co-expression matrices associated
to complexes
The most widely used choice for quantifying gene co-
expression are covariance-based measures like Pearson
correlation (linear measure) or entropy-based like the
mutual information (nonlinear measure). These simple
pairwise similarity measures are computationally tract-
able, although they may suffer from high false discovery
rate, i.e., genes are erroneously associated while in truth
they only indirectly interact through one or more other
genes. We used Pearson correlation of gene expression
profiles to infer the co-expression of a pair of genesFigure 5 Distribution of correlation values. The distribution of correlations
mouse at 1 month of age. On the x-axis there are the co-expression values
into two classes, based on the number N of genes: small with N < =10 (leftwithin the same complex. In this way we computed
n × (n − 1)/2 pairs of values for a complex with n pro-
teins and represented them using an upper triangular
matrix indexed by the proteins IDs.
Gene correlation strength within protein complexes
As a preliminary assessment, the question of whether there
exists a relation between the similarity in gene co-
expression profiles and protein complexes was addressed in
our transgenic control mice vs. wild type. As a first step, we
checked if in the chosen control mice there was a bias of
the overall gene-gene correlation structure of expression
profiles: at this purpose we first compared the control
mouse profiles to publicly available wild mice profiles. We
computed the Pearson correlation for each pair of genes in
the same complex using the dataset of control mice at
1 month of age. As mentioned, we used CORUM [81] as
the reference dataset for protein complexes. The number of
genes in complexes of our dataset varies considerably, ran-
ging from 3 to 40, but the vast majority of the complexes
are small. For instance, around 95% of protein complexes
have size smaller than 10 genes. Thus, as in previous works,
we divided complexes into two classes: small (<=10) and
large complexes (>10) and analyze them separately [76].
The distributions of the correlations in small and large
complexes are shown in Figure 5 for the control mouse at
1 month of age.
Both distributions appear to be centered around zero.
Thus, unlike previous studies conducted on yeast and hu-
man cells [6,75-77], we did not observe a shift to the right
(average positive correlation) of the distribution of large
complexes of control mouse. To verify whether this was a
property peculiar to the control mouse strain chosen in this
study, we performed the same preliminary analysis also
using the wild type mouse dataset E-GEOD-4734 available
from the public gene expression repository Array Express
[82], which contains five mouse brain regions including
hippocampus in six mouse strains. The distributions for theof gene expression profiles within protein complexes in the control
of pairs of proteins within complexes. The complexes are separated
) and large with N > 10 (right).
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mouse with average value close to zero. Therefore we con-
cluded that the chosen control was suitable as reference for
the analysis carried out in this work.
Variation in average gene co-expression
For a given protein complex, let A and B be the matrices
of co-expression values associated with genes inside the
complex of AD11 and control samples, respectively, at
the same time point. For each matrix, the average was
taken over all the elements of the upper triangular
matrix (excluding the diagonal). The difference of the
averages of A and B was then computed and this com-
putation was repeated for all four time points. This stat-
istic gives an idea of the variation over time of the
expression levels of genes inside a complex for the two
classes of samples.
A statistical test to evaluate the significance of the
change in average co-expression value within a complex
was applied. A natural correspondence between data
values at the same positions in the two matrices, i.e. Aij
and Bij corresponding to the same two genes i and j,
suggested the use of a paired t-student test. Precisely,

















Where N = n × (n-1)/2 and n is the size of a complex.
If t exceeds the t distribution reference value for a cer-
tain probability value, then the averages are significantly
different at that probability level. We chose, as is gener-
ally the case, the probability value p = 0.05 (p-value).
The significance variations in the averages at the 4








Distance of gene co-expression matrices
Given two correlation matrices A and B corresponding
to AD11 and control samples at the same month, we
adopted the Euclidean distance between the two matri-
ces as an inverse measure of their similarity. It is defined
as the square root of the average squared difference be-








where N = n × (n − 1)/2 and n is the size of a complex.
We note that the proposed measure weights the cor-
relation between all pairs of genes in the same way,and does not possess a theoretical maximum value
(its minimum being 0). This does not allow any
normalization of d. Thus we resorted to a statistical
test to provide a significance measure of d. We deter-
mined the average distance of AD11 and control for a
collection of random complexes, then computed the z-
score for the distance value d of an observed complex
with respect to the random complexes. Precisely, for
each complex size n we generated a set of 1000 ran-
dom complexes consisting of n randomly selected
genes and their expression values. We did that for
each of the two classes AD11 and control and for each
of the four time points. The significance z of the ob-
served d at a given time point and for any given com-
plex size n was transformed into a z-score through the
relation z = (d − < x >)2/S, where < x > is the average
over all random samples of size n of the distances be-
tween AD11 and control matrices, and S denotes the
standard deviation of the same distances. This z-score
represents the chance that a random complex, consist-
ing of a group of n randomly selected genes, could
exhibit a distance of gene co-expression matrices be-
tween AD11 and control greater than or equal to that
of the observed complex. In our test we chose a z-
score of 1.9 as a threshold of significance.
Availability of supporting data
The whole Agilent microarray dataset used in this study
is publicly available from the Gene Expression Omnibus




The authors have no commercial association that might create a competing
interest in connection with the submitted manuscript.
Authors’ contributions
PB, CG, GF, MD, IA, AC: conception and design; MD, RB, IA acquisition of
data; FC, GF, PB, CG, IA analysis and interpretation of data; PB, CG, GF, FC,
MD, IA, RB, AC: drafting and revising the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
We would like to acknowledge Simona Capsoni (SNS, Pisa, Italy) for her
advice during the early phases of the AD11 project, Flavia Ricevuti, Sabrina
Turturro and Daniele Pietrucci (Genomics Facility, EBRI, Roma, Italy) for
technical contributions and data analysis. All members of the
Neurodegenerative Diseases and Neurotrophic Factors Laboratory (EBRI,
Roma, Italy) are gratefully acknowledged for helpful discussions.
This research was supported by the following grants: FIRB RBAP10L8TY from
the Italian Ministry of Education, University and Research (MIUR); grant from
Fondazione Roma; PRIN 2010N8PBAA_006 from the Italian Ministry of
Education, University and Research (MIUR); PAINCAGE FP7 Collaborative
Project num. 603191; FLAGSHIP “InterOmics” italian project (PB.P05) from the
Italian Ministry of Education; Italian Foundation for Multiple Sclerosis (FISM)
2013/R/6.
Author details
1Genomics Facility, European Brain Research Institute (EBRI) Rita
Levi-Montalcini, Via del Fosso di Fiorano, 64, 00143 Rome, Italy.
Arisi et al. BMC Neuroscience  (2015) 16:28 Page 14 of 152Neurotrophic Factors and Neurodegenerative Diseases Unit, EBRI, Rome,
Italy. 3Scuola Normale Superiore, Piazza dei Cavalieri 7, 56126 Pisa, Italy.
4Istituto di Analisi dei Sistemi ed Informatica “Antonio Ruberti” (IASI-CNR),
Rome, Italy. 5College of Computing, Georgia Institute of Technology, Atlanta,
GA, USA.
Received: 1 December 2014 Accepted: 11 March 2015
References
1. Bertolazzi P, Bock ME, Guerra C. On the functional and structural
characterization of hubs in protein-protein interaction networks. Biotechnol
Adv. 2013;31:274–86.
2. Levy ED, Pereira-Leal JB. Evolution and dynamics of protein interactions and
networks. Curr Opin Struct Biol. 2008;18:349–57.
3. Przytycka TM, Singh M, Slonim DK. Toward the dynamic interactome: it’s
about time. Brief Bioinform. 2010;11:15–29.
4. Stelzl U, Wanker EE. The value of high quality protein-protein interaction
networks for systems biology. Curr Opin Chem Biol. 2006;10:551–8.
5. Vidal M, Cusick ME, Barabasi AL. Interactome networks and human disease.
Cell. 2011;144:986–98.
6. Jansen R, Greenbaum D, Gerstein M. Relating whole-genome expression
data with protein-protein interactions. Genome Res. 2002;12:37–46.
7. Tuncbag N, Kar G, Gursoy A, Keskin O, Nussinov R. Towards inferring time
dimensionality in protein-protein interaction networks by integrating
structures: the p53 example. Mol Biosyst. 2009;5:1770–8.
8. de Lichtenberg U, Jensen LJ, Brunak S, Bork P. Dynamic complex formation
during the yeast cell cycle. Science. 2005;307:724–7.
9. Srihari S, Leong HW. Temporal dynamics of protein complexes in PPI
networks: a case study using yeast cell cycle dynamics. BMC Bioinf.
2012;17(13 Suppl):S16.
10. Tang X, Wang J, Liu B, Li M, Chen G, Pan Y. A comparison of the functional
modules identified from time course and static PPI network data. BMC
Bioinf. 2011;12:339.
11. Taylor IW, Linding R, Warde-Farley D, Liu Y, Pesquita C, Faria D, et al.
Dynamic modularity in protein interaction networks predicts breast cancer
outcome. Nat Biotechnol. 2009;27:199–204.
12. Wang J, Peng X, Li M, Pan Y. Construction and application of dynamic
protein interaction network based on time course gene expression data.
Proteomics. 2013;13:301–12.
13. Vlasblom J, Wodak SJ. Markov clustering versus affinity propagation for the
partitioning of protein interaction graphs. BMC Bioinf. 2009;10:99.
14. Palla G, Derenyi I, Farkas I, Vicsek T. Uncovering the overlapping community
structure of complex networks in nature and society. Nature.
2005;435:814–8.
15. Bader GD, Hogue CW. An automated method for finding molecular
complexes in large protein interaction networks. BMC Bioinf. 2003;4:2.
16. Ciriello G, Mina M, Guzzi PH, Cannataro M, Guerra C. AlignNemo: a local
network alignment method to integrate homology and topology. PLoS
One. 2012;7:e38107.
17. Arisi I, D’Onofrio M, Brandi R, Felsani A, Capsoni S, Drovandi G, et al. Gene
expression biomarkers in the brain of a mouse model for Alzheimer’s
disease: mining of microarray data by logic classification and feature
selection. J Alzheimers Dis. 2011;24:721–38.
18. D’Onofrio M, Arisi I, Brandi R, Di Mambro A, Felsani A, Capsoni S, et al. Early
inflammation and immune response mRNAs in the brain of AD11 anti-NGF
mice. Neurobiol Aging. 2011;32:1007–22.
19. Capsoni S, Brandi R, Arisi I, D’Onofrio M, Cattaneo A. A dual mechanism
linking NGF/proNGF imbalance and early inflammation to Alzheimer’s
disease neurodegeneration in the AD11 anti-NGF mouse model. CNS Neurol
Disord Drug Targets. 2011;10:635–47.
20. Ruberti F, Capsoni S, Comparini A, Di Daniel E, Franzot J, Gonfloni S, et al.
Phenotypic knockout of nerve growth factor in adult transgenic mice
reveals severe deficits in basal forebrain cholinergic neurons, cell death in
the spleen, and skeletal muscle dystrophy. J Neurosci. 2000;20:2589–601.
21. Fujiyama S, Yanagida M, Hayano T, Miura Y, Isobe T, Fujimori F, et al.
Isolation and proteomic characterization of human Parvulin-associating
preribosomal ribonucleoprotein complexes. J Biol Chem. 2002;277:23773–80.
22. Mueller JW, Bayer P. Small family with key contacts: par14 and par17
parvulin proteins, relatives of pin1, now emerge in biomedical research.
Perspect Medicin Chem. 2008;2:11–20.23. Ando K, Dourlen P, Sambo AV, Bretteville A, Belarbi K, Vingtdeux V, et al. Tau
pathology modulates Pin1 post-translational modifications and may be
relevant as biomarker. Neurobiol Aging. 2013;34:757–69.
24. Kimura T, Tsutsumi K, Taoka M, Saito T, Masuda-Suzukake M, Ishiguro K,
et al. Isomerase Pin1 stimulates dephosphorylation of tau protein at cyclin-
dependent kinase (Cdk5)-dependent Alzheimer phosphorylation sites. J Biol
Chem. 2013;288:7968–77.
25. Pastorino L, Ma SL, Balastik M, Huang P, Pandya D, Nicholson L, et al. Alzheimer’s
disease-related loss of Pin1 function influences the intracellular localization and
the processing of AbetaPP. J Alzheimers Dis. 2012;30:277–97.
26. Wang JZ, Zhang YH, Sun XW, Li YL, Li SR, Zhang Y, et al. Focusing on the
structure and the function of Pin1: new insights into the opposite effects of
fever on cancers and Alzheimer’s disease. Med Hypotheses. 2013;81:282–4.
27. Jung C, Mittler G, Oswald F, Borggrefe T. RNA helicase Ddx5 and the
noncoding RNA SRA act as coactivators in the Notch signaling pathway.
Biochim Biophys Acta. 1833;2013:1180–9.
28. Ghosh S, Thakur MK. Interaction of estrogen receptor-alpha transactivation
domain with nuclear proteins of mouse brain: p68 RNA helicase shows age-
and sex-specific change. J Neurosci Res. 2009;87:1323–8.
29. Arun G, Akhade VS, Donakonda S, Rao MR. mrhl RNA, a long noncoding
RNA, negatively regulates Wnt signaling through its protein partner Ddx5/
p68 in mouse spermatogonial cells. Mol Cell Biol. 2012;32:3140–52.
30. Wang R, Jiao Z, Li R, Yue H, Chen L. p68 RNA helicase promotes glioma cell
proliferation in vitro and in vivo via direct regulation of NF-kappaB
transcription factor p50. Neuro Oncol. 2012;14:1116–24.
31. Kar A, Fushimi K, Zhou X, Ray P, Shi C, Chen X, et al. RNA helicase p68
(DDX5) regulates tau exon 10 splicing by modulating a stem-loop structure
at the 5′ splice site. Mol Cell Biol. 2011;31:1812–21.
32. Agholme L, Nath S, Domert J, Marcusson J, Kagedal K, Hallbeck M.
Proteasome inhibition induces stress kinase dependent transport deficits–
implications for Alzheimer’s disease. Mol Cell Neurosci. 2014;58:29–39.
33. Chesser AS, Pritchard SM, Johnson GV. Tau clearance mechanisms and their
possible role in the pathogenesis of Alzheimer disease. Front Neurol.
2013;4:122.
34. Ghavami S, Shojaei S, Yeganeh B, Ande SR, Jangamreddy JR, Mehrpour M,
et al. Autophagy and apoptosis dysfunction in neurodegenerative disorders.
Prog Neurobiol. 2014;112:24–49.
35. Saido T, Leissring MA. Proteolytic degradation of amyloid beta-protein. Cold
Spring Harb Perspect Med. 2012;2:a006379.
36. Cecarini V, Bonfili L, Amici M, Angeletti M, Keller JN, Eleuteri AM. Amyloid
peptides in different assembly states and related effects on isolated and
cellular proteasomes. Brain Res. 2008;1209:8–18.
37. Orre M, Kamphuis W, Dooves S, Kooijman L, Chan ET, Kirk CJ, et al. Reactive
glia show increased immunoproteasome activity in Alzheimer’s disease.
Brain. 2013;136:1415–31.
38. Yen SS. Proteasome degradation of brain cytosolic tau in Alzheimer’s
disease. Int J Clin Exp Pathol. 2011;4:385–402.
39. Ferrington DA, Gregerson DS. Immunoproteasomes: structure, function, and
antigen presentation. Prog Mol Biol Transl Sci. 2012;109:75–112.
40. Foss GS, Larsen F, Solheim J, Prydz H. Constitutive and interferon-gamma-
induced expression of the human proteasome subunit multicatalytic
endopeptidase complex-like 1. Biochim Biophys Acta. 1998;1402:17–28.
41. Hussong SA, Kapphahn RJ, Phillips SL, Maldonado M, Ferrington DA.
Immunoproteasome deficiency alters retinal proteasome’s response to
stress. J Neurochem. 2010;113:1481–90.
42. Heink S, Ludwig D, Kloetzel PM, Kruger E. IFN-gamma-induced immune
adaptation of the proteasome system is an accelerated and transient
response. Proc Natl Acad Sci U S A. 2005;102:9241–6.
43. Jia Y, Song T, Wei C, Ni C, Zheng Z, Xu Q, et al. Negative regulation of
MAVS-mediated innate immune response by PSMA7. J Immunol.
2009;183:4241–8.
44. Hu XT, Chen W, Zhang FB, Shi QL, Hu JB, Geng SM, et al. Depletion of the
proteasome subunit PSMA7 inhibits colorectal cancer cell tumorigenicity
and migration. Oncol Rep. 2009;22:1247–52.
45. Berhane S, Areste C, Ablack JN, Ryan GB, Blackbourn DJ, Mymryk JS, et al.
Adenovirus E1A interacts directly with, and regulates the level of expression
of, the immunoproteasome component MECL1. Virology. 2011;421:149–58.
46. Aso E, Lomoio S, Lopez-Gonzalez I, Joda L, Carmona M, Fernandez-Yague N,
et al. Amyloid generation and dysfunctional immunoproteasome activation
with disease progression in animal model of familial Alzheimer’s disease.
Brain Pathol. 2012;22:636–53.
Arisi et al. BMC Neuroscience  (2015) 16:28 Page 15 of 1547. Mishto M, Bellavista E, Santoro A, Stolzing A, Ligorio C, Nacmias B, et al.
Immunoproteasome and LMP2 polymorphism in aged and Alzheimer’s
disease brains. Neurobiol Aging. 2006;27:54–66.
48. Tsai KL, Tomomori-Sato C, Sato S, Conaway RC, Conaway JW, Asturias FJ.
Subunit architecture and functional modular rearrangements of the
transcriptional mediator complex. Cell. 2014;157:1430–44.
49. Carlsten JO, Zhu X, Gustafsson CM. The multitalented Mediator complex.
Trends Biochem Sci. 2013;38:531–7.
50. Schiano C, Casamassimi A, Vietri MT, Rienzo M, Napoli C. The roles of
mediator complex in cardiovascular diseases. Biochim Biophys Acta.
1839;2014:444–51.
51. Wang X, Yang N, Uno E, Roeder RG, Guo S. A subunit of the mediator
complex regulates vertebrate neuronal development. Proc Natl Acad Sci U
S A. 2006;103:17284–9.
52. Lande-Diner L, Boyault C, Kim JY, Weitz CJ. A positive feedback loop links
circadian clock factor CLOCK-BMAL1 to the basic transcriptional machinery.
Proc Natl Acad Sci U S A. 2013;110:16021–6.
53. Musiek ES, Lim MM, Yang G, Bauer AQ, Qi L, Lee Y, et al. Circadian clock
proteins regulate neuronal redox homeostasis and neurodegeneration. J
Clin Invest. 2013;123:5389–400.
54. Lariviere L, Plaschka C, Seizl M, Wenzeck L, Kurth F, Cramer P. Structure of
the Mediator head module. Nature. 2012;492:448–51.
55. Furumoto T, Tanaka A, Ito M, Malik S, Hirose Y, Hanaoka F, et al. A kinase
subunit of the human mediator complex, CDK8, positively regulates
transcriptional activation. Genes Cells. 2007;12:119–32.
56. Soreq H. Novel roles of non-coding brain RNAs in health and disease. Front
Mol Neurosci. 2014;7:55.
57. Kong Y, Wu J, Yuan L. MicroRNA expression analysis of adult-onset
Drosophila Alzheimer’s disease model. Curr Alzheimer Res. 2014;11:882–91.
58. Rodriguez-Ortiz CJ, Baglietto-Vargas D, Martinez-Coria H, LaFerla FM,
Kitazawa M. Upregulation of miR-181 decreases c-Fos and SIRT-1 in the
hippocampus of 3xTg-AD mice. J Alzheimers Dis. 2014;42:1229–38.
59. Galimberti D, Villa C, Fenoglio C, Serpente M, Ghezzi L, Cioffi SM, et al.
Circulating miRNAs as potential biomarkers in Alzheimer’s disease. J
Alzheimers Dis. 2014;42:1261–7.
60. Tan L, Yu JT, Tan MS, Liu QY, Wang HF, Zhang W, et al. Genome-wide serum
microRNA expression profiling identifies serum biomarkers for Alzheimer’s
disease. J Alzheimers Dis. 2014;40:1017–27.
61. Lau P, Bossers K, Janky R, Salta E, Frigerio CS, Barbash S, et al. Alteration of
the microRNA network during the progression of Alzheimer’s disease. EMBO
Mol Med. 2013;5:1613–34.
62. Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q, et al. The
expression of microRNA miR-107 decreases early in Alzheimer’s disease and
may accelerate disease progression through regulation of beta-site amyloid
precursor protein-cleaving enzyme 1. J Neurosci. 2008;28:1213–23.
63. Lee ST, Chu K, Im WS, Yoon HJ, Im JY, Park JE, et al. Altered microRNA
regulation in Huntington’s disease models. Exp Neurol. 2011;227:172–9.
64. Hebert SS, Papadopoulou AS, Smith P, Galas MC, Planel E, Silahtaroglu AN,
et al. Genetic ablation of Dicer in adult forebrain neurons results in
abnormal tau hyperphosphorylation and neurodegeneration. Hum Mol
Genet. 2010;19:3959–69.
65. Uchida Y, Takio K, Titani K, Ihara Y, Tomonaga M. The growth inhibitory
factor that is deficient in the Alzheimer’s disease brain is a 68 amino acid
metallothionein-like protein. Neuron. 1991;7:337–47.
66. El Ghazi I, Martin BL, Armitage IM. New proteins found interacting with
brain metallothionein-3 are linked to secretion. Int J Alzheimers Dis.
2010;2011:208634.
67. Luo Y, Xu Y, Bao Q, Ding Z, Zhu C, Huang ZX, et al. The molecular
mechanism for human metallothionein-3 to protect against the neuronal
cytotoxicity of Abeta(1–42) with Cu ions. J Biol Inorg Chem. 2013;18:39–47.
68. Manso Y, Carrasco J, Comes G, Meloni G, Adlard PA, Bush AI, et al.
Characterization of the role of metallothionein-3 in an animal model of
Alzheimer’s disease. Cell Mol Life Sci. 2012;69:3683–700.
69. Slaymaker IM, Chen XS. MCM structure and mechanics: what we have
learned from archaeal MCM. Subcell Biochem. 2012;62:89–111.
70. Bonda DJ, Evans TA, Santocanale C, Llosa JC, Vina J, Bajic V, et al. Evidence
for the progression through S-phase in the ectopic cell cycle re-entry of
neurons in Alzheimer disease. Aging (Albany NY). 2009;1:382–8.
71. Schrotter A, Mastalski T, Nensa FM, Neumann M, Loosse C, Pfeiffer K, et al.
FE65 regulates and interacts with the Bloom syndrome protein in dynamicnuclear spheres - potential relevance to Alzheimer’s disease. J Cell Sci.
2013;126:2480–92.
72. Frade JM, Ovejero-Benito MC. Neuronal cell cycle: the neuron itself and its
circumstances. Cell Cycle. 2015;14:712–20.
73. Takata K, Kitamura Y, Nakata Y, Matsuoka Y, Tomimoto H, Taniguchi T, et al.
Involvement of WAVE accumulation in Abeta/APP pathology-dependent
tangle modification in Alzheimer’s disease. Am J Pathol. 2009;175:17–24.
74. Yamamoto A, Behl C. Human Nck-associated protein 1 and its binding protein
affect the metabolism of beta-amyloid precursor protein with Swedish mutation.
Neurosci Lett. 2001;316:50–4.
75. Kikugawa S, Nishikata K, Murakami K, Sato Y, Suzuki M, Altaf-Ul-Amin M,
et al. PCDq: human protein complex database with quality index which
summarizes different levels of evidences of protein complexes predicted
from h-invitational protein-protein interactions integrative dataset. BMC Syst
Biol. 2012;6 Suppl 2:S7.
76. Liu CT, Yuan S, Li KC. Patterns of co-expression for protein complexes by
size in Saccharomyces cerevisiae. Nucleic Acids Res. 2009;37:526–32.
77. Tornow S, Mewes HW. Functional modules by relating protein interaction
networks and gene expression. Nucleic Acids Res. 2003;31:6283–9.
78. Laganowsky A, Reading E, Hopper JT, Robinson CV. Mass spectrometry of
intact membrane protein complexes. Nat Protoc. 2013;8:639–51.
79. Cattaneo A, Rapposelli B, Calissano P. Three distinct types of monoclonal
antibodies after long-term immunization of rats with mouse nerve growth
factor. J Neurochem. 1988;50:1003–10.
80. Covaceuszach S, Cassetta A, Konarev PV, Gonfloni S, Rudolph R, Svergun DI,
et al. Dissecting NGF interactions with TrkA and p75 receptors by structural
and functional studies of an anti-NGF neutralizing antibody. J Mol Biol.
2008;381:881–96.
81. Ruepp A, Brauner B, Dunger-Kaltenbach I, Frishman G, Montrone C, Stransky
M, et al. CORUM: the comprehensive resource of mammalian protein
complexes. Nucleic Acids Res. 2008;36:D646–50.
82. Hovatta I, Zapala MA, Broide RS, Schadt EE, Libiger O, Schork NJ, et al. DNA
variation and brain region-specific expression profiles exhibit different
relationships between inbred mouse strains: implications for eQTL mapping
studies. Genome Biol. 2007;8:R25.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
